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More than 300 associations between 
genetic variants and common diseases have 
been identified in recent years (Hindorff et 
al., 2009; Golka et al., 2009, 2011, 2012; 
Kiemeney et al., 2010; Binder et al., 2012). 
For cancer, most variants, also called 
single nucleotide polymorphism (SNP), 
confer only a moderate risk with odds ratios 
less than 1.5 (Lichtenstein et al., 2000; 
Selinski et al., 2012a, b, 2011; Lehmann et 
al., 2010; Ovsiannikov et al., 2012; Rafnar 
et al., 2011). Until recently, it was unknown 
whether interaction among the high-risk 
alleles of several genetic variants would 
lead to an increased cancer risk (Bolt, 
2013a, b; Stewart and Marchan, 2012). This 
was addressed in a recent study by Holger 
Schwender and colleagues who investigated 
the interaction among SNPs known to be 
associated with bladder cancer and risk. 
Their results clearly show increased overall 
risk, causing much excitement in the field 
(Schwender et al., 2012).  
In their work, the group from Dort-
mund, Germany, showed that for single 
SNPs, for example rs1014971 and 
rs9642680, the odds ratio are 1.63 and 1.48, 
respectively. However, combining both 
SNPs resulted in an increased odds ratio of 
1.91 (Schwender et al., 2012) – a ratio larg-
er than the individual effects but smaller 
than additive (1.63 + 1.48 = 3.11). Includ-
ing a third SNP also increased the odds ra-
tio, but only by a further 0.07 (Schwender 
et al., 2012). Using an elegant statistical 
approach and testing stability by bootstrap-
ping, the authors demonstrate that stable 
combinations of up to three high-risk alleles 
result in odds ratios of up to 2.0 in non-
smokers. This is clearly higher than the in-
fluence of individual high-risk alleles, but 
also less than the additive risk. 
Although the study of Schwender 
(Schwender et al., 2012) represents remark-
able progress, one important question re-
mains open. What would happen if more 
high-risk variants were added to the three-
way interactions? Would there be a relevant 
further increase in the cancer risk? Or, 
would odds ratios asymptotically approach 
a ‘natural’ upper limit of 2.0 or slightly 
above? Schwender and colleagues could not 
answer this question due to the limited case 
numbers (1,593 urinary bladder cases and 
1,760 controls). Therefore, four-way or 
even higher interactions could not be evalu-
ated because the combination results were 
no longer stable after bootstrapping.  
In conclusion, there is a definite need to 
bring together all data on genetic variants 
that is available world-wide. The increased 
statistical power will facilitate studies of 
interactions, and advance our understanding 
on how genetic variants interact to cause 
increased cancer risk. 
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